Greatwall promotes cell transformation by hyperactivating AKT in human malignancies

  1. Jorge Vera
  2. Lydia Lartigue
  3. Suzanne Vigneron
  4. Gilles Gadea
  5. Veronique Gire
  6. Maguy Del Rio
  7. Isabelle Soubeyran
  8. Frederic Chibon
  9. Thierry Lorca
  10. Anna Castro  Is a corresponding author
  1. Université de Montpellier, France
  2. Université Bordeaux Segalen, France
  3. Institut de Recherche en Cancérologie de Montpellier, France

Abstract

The PP2A phosphatase is often inactivated in cancer and is considered as a tumour suppressor. A new pathway controlling PP2A activity in mitosis has been recently described. This pathway includes the Greatwall (GWL) kinase and its substrates endosulfines. At mitotic entry, GWL is activated and phosphorylates endosulfines that then bind and inhibit PP2A. We analysed whether GWL overexpression could participate in cancer development. We show that GWL overexpression promotes cell transformation and increases invasive capacities of cells through hyperphosphorylation of the oncogenic kinase AKT. Interestingly, AKT hyperphosphorylation induced by GWL is independent of endosulfines. Rather, GWL induces GSK3 kinase dephosphorylation in its inhibitory sites and subsequent SCF-dependent degradation of the PHLPP phosphatase responsible for AKT dephosphorylation. In line with its oncogenic activity, we find that GWL is often overexpressed in human colorectal tumoral tissues. Thus, GWL is a human onocoprotein that promotes the hyperactivation of AKT via the degradation of its phosphatase, PHLPP, in human malignancies.

Article and author information

Author details

  1. Jorge Vera

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Lydia Lartigue

    Department of Medical Oncology, Institut Bergonié, Institut National de la Santé et de la Recherche Medicale, Université Bordeaux Segalen, Bordeux, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Suzanne Vigneron

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Gilles Gadea

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Veronique Gire

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Maguy Del Rio

    Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Isabelle Soubeyran

    Department of Medical Oncology, Institut Bergonié, Institut National de la Santé et de la Recherche Medicale, Université Bordeaux Segalen, Bordeaux, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Frederic Chibon

    Department of Medical Oncology, Institut Bergonié, Institut National de la Santé et de la Recherche Medicale, Université Bordeaux Segalen, Bordeaux, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Thierry Lorca

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Anna Castro

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    For correspondence
    anna.castro@crbm.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. James Ferrell, Stanford University, United States

Ethics

Animal experimentation: All animal experiments conformed to the relevant regulatory standards and were approved by the Ethics Local Committee of the IRCM (Institut de Recherche en Cancérologie de Montpellier) and by the Regional Ethic Commitée of the "Languedoc Roussillon"(France). Ref: 1137.

Human subjects: Human Samples for TMA:Cases were issued from the archives of the Department of Pathology of Bergonie Institute (Bordeaux, France). For all samples, ethical approval was obtained from the appropriate committees. Cases were then centralised in the Biological Resources Center of Bergonie Institute, which has received the agreement from the French authorities to deliver samples for scientific research (AC-2008-812)."The TMA used in this study has been moreover used in three other published studies (See: Soubeyran and al., Am J of Pathology 2011, Rey and al., Cell Cycle 2013 and Oncogene 2015).For colorectal tumour samples used for western blot:The study was approved by the ICM CORT (Translational Research Committee) ethical committee and all participating patients were informed of the study and provided their signed written informed consent before enrolment. This set of samples were already used in Del Rio et al., JCO 2007 and Del Rio et al, Plos one 2013.

Version history

  1. Received: July 15, 2015
  2. Accepted: November 26, 2015
  3. Accepted Manuscript published: November 27, 2015 (version 1)
  4. Version of Record published: January 18, 2016 (version 2)

Copyright

© 2015, Vera et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,719
    views
  • 459
    downloads
  • 42
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jorge Vera
  2. Lydia Lartigue
  3. Suzanne Vigneron
  4. Gilles Gadea
  5. Veronique Gire
  6. Maguy Del Rio
  7. Isabelle Soubeyran
  8. Frederic Chibon
  9. Thierry Lorca
  10. Anna Castro
(2015)
Greatwall promotes cell transformation by hyperactivating AKT in human malignancies
eLife 4:e10115.
https://doi.org/10.7554/eLife.10115

Share this article

https://doi.org/10.7554/eLife.10115

Further reading

    1. Cell Biology
    Joanne Tung, Lei Huang ... Adriana Ordonez
    Research Article

    Activating transcription factor 6 (ATF6) is one of three endoplasmic reticulum (ER) transmembrane stress sensors that mediate the unfolded protein response (UPR). Despite its crucial role in long-term ER stress adaptation, regulation of ATF6 alpha (α) signalling remains poorly understood, possibly because its activation involves ER-to-Golgi and nuclear trafficking. Here, we generated an ATF6α/Inositol-requiring kinase 1 (IRE1) dual UPR reporter CHO-K1 cell line and performed an unbiased genome-wide CRISPR/Cas9 mutagenesis screen to systematically profile genetic factors that specifically contribute to ATF6α signalling in the presence and absence of ER stress. The screen identified both anticipated and new candidate genes that regulate ATF6α activation. Among these, calreticulin (CRT), a key ER luminal chaperone, selectively repressed ATF6α signalling: Cells lacking CRT constitutively activated a BiP::sfGFP ATF6α-dependent reporter, had higher BiP levels and an increased rate of trafficking and processing of ATF6α. Purified CRT interacted with the luminal domain of ATF6α in vitro and the two proteins co-immunoprecipitated from cell lysates. CRT depletion exposed a negative feedback loop implicating ATF6α in repressing IRE1 activity basally and overexpression of CRT reversed this repression. Our findings indicate that CRT, beyond its known role as a chaperone, also serves as an ER repressor of ATF6α to selectively regulate one arm of the UPR.

    1. Cancer Biology
    2. Cell Biology
    Alex Weiss, Cassandra D'Amata ... Madeline N Hayes
    Research Article

    High-throughput vertebrate animal model systems for the study of patient-specific biology and new therapeutic approaches for aggressive brain tumors are currently lacking, and new approaches are urgently needed. Therefore, to build a patient-relevant in vivo model of human glioblastoma, we expressed common oncogenic variants including activated human EGFRvIII and PI3KCAH1047R under the control of the radial glial-specific promoter her4.1 in syngeneic tp53 loss-of-function mutant zebrafish. Robust tumor formation was observed prior to 45 days of life, and tumors had a gene expression signature similar to human glioblastoma of the mesenchymal subtype, with a strong inflammatory component. Within early stage tumor lesions, and in an in vivo and endogenous tumor microenvironment, we visualized infiltration of phagocytic cells, as well as internalization of tumor cells by mpeg1.1:EGFP+ microglia/macrophages, suggesting negative regulatory pressure by pro-inflammatory cell types on tumor growth at early stages of glioblastoma initiation. Furthermore, CRISPR/Cas9-mediated gene targeting of master inflammatory transcription factors irf7 or irf8 led to increased tumor formation in the primary context, while suppression of phagocyte activity led to enhanced tumor cell engraftment following transplantation into otherwise immune-competent zebrafish hosts. Altogether, we developed a genetically relevant model of aggressive human glioblastoma and harnessed the unique advantages of zebrafish including live imaging, high-throughput genetic and chemical manipulations to highlight important tumor-suppressive roles for the innate immune system on glioblastoma initiation, with important future opportunities for therapeutic discovery and optimizations.